ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-MUC-1/Anti-CD40 Bispecific Antibody M0324

Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Merck KGaA, Darmstadt, Germany.

Furthest: phase 1, since Sep 3, 20251 company-led study, 1 open or runningNext primary completion: Feb 23, 2029 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck KGaA, Darmstadt, Germany11 open or runningphase 1since Sep 3, 2025Sep 3, 2025Feb 23, 2029phase 1 · NCT07166601

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 3, 2025First study: phase 1 study in Medullary cystic kidney disease 1First studyNCT07166601 · 77 planned · United States, Canada, Japan

Ahead

  1. Feb 23, 2029Primary completion: phase 1 study in Medullary cystic kidney disease 1NCT07166601

TargetBeta

CD40 →MUC1 →read by rule
“A bispecific antibody directed against both the tumor-associated antigen (TAA) mucin-1 (MUC-1; MUC1) and the cell surface receptor CD40, ”NCIt, by rule

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07166601Medullary cystic kidney disease 1 · United States, Canada, Japan1RecruitingFeb 23, 202977

How it is read

Names in the registry

  • “M0324”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.